These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Ongoing 2008-000948-13 Etude de phase II, multicentrique, en ouvert, évaluant l'efficacité d'un traitement par Sutent (sunitinib) chez des patients porteurs de métastases cérébrales d'origine rénale non traitées antérieurem... not-yet-due
Completed, but no date 2008-005068-14 Etude de phase II d’intensification de dose dans les tumeurs germinales réfractaires et en rechute de mauvais pronostic Protocole TICE : Paclitaxel et Ifosfamide suivi par une intensification de Carb... bad-data
Completed, but no date 2009-018090-30 Hormonothérapie adjuvante du cancer du sein : Pharmacocinétique du tamoxifène et des anti-aromatases, corrélation avec les caractéristiques pharmacogénétiques Protocole PHACS (Pharmacologie de l’Hormo... bad-data
Exempt 2016-001614-16 A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma. Essai... not-yet-due
Completed, but no date 2017-004814-24 Pharmacologic interaction between Ifosfamide and Aprepitant in treated patients with soft tissue sarcoma. Interaction Pharmacologique entre Ifosfamide et APrépitant chez les patients traités pour u... bad-data
Completed, but no date Terminated 2018-001552-36 The use of FES-PET imaging as a tool to detect a possible reversion of Estrogen Receptor (ER)-α status in patients with metastatic breast cancer HER2 + and ERα neg treated with trastuzumab + pertuzuma... bad-data
Ongoing 2018-004490-27 A multicentric Phase II, open-label study evaluating the efficacy of the combination of hypofractionated stereotactic radiation therapy with the anti-PDL1 immune checkpoint inhibitor Durvalumab in NSC... not-yet-due
Ongoing 2019-003014-13 Interest of peri operative CHemotherapy In patients with CINSARC high-risk localized grade 1 or 2 Soft Tissue Sarcoma. Intérêt de la chimiothérapie péri-opératoire chez les patients porteurs de sar... not-yet-due
Exempt 2020-002996-36 A Phase I Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTA0-Tyr3-Octreotate in Children with Refractory or Recurrent Neuroblastoma expressing somato... not-yet-due